Journal of the American Psychiatric Nurses Association
August 10, 2023
G. Pearson
The use of psychedelic medications to treat the brain disorders associated with psychiatric illness has re-emerged in recent years as a viable treatment option (Grieco et al., 2022). Historically there is evidence of hallucinogenic use in religious and spiritual rituals dating back to 500 B.C. (Begola & Dowben, 2018). The discovery of LSD (lysergic acid diethylamine-25) in Switzerland in 1943...
Harm Reduction Journal
August 9, 2023
Hagit Bonny-Noach, Barak Shapira, Pinchas Baumol et al.
9 citations
Few studies have analyzed harm reduction behaviors and attitudes among rave party attendees. Since the late 1980s, there has been a large Israeli rave scene, also known as 'Nature Parties'. However, only a few studies have been conducted among nature party attendees and almost all of them are from a qualitative perspective. This study's aim was to fill the gap and conduct quantitative research...
Rehabilitation psychology
August 1, 2023
Aaron P Turner, Karlyn A Edwards, Mark P Jensen et al.
5 citations
To examine the impact of three behavioral interventions for chronic pain on substance use. Participants were 328 Veterans with chronic pain receiving care at one of two Veterans Affairs Medical Centers in the northwest United States. Participants were randomly assigned to one of three 8-week manualized in-person group treatments: (a) hypnosis (HYP), (b) mindfulness meditation (MM), or (c)...
Clinics in geriatric medicine
August 1, 2023
Kabir Nigam, Kimberly A Curseen, Yvan Beaussant
3 citations
Psychological distress at the end of life is a common experience that lacks effective treatments. This is in part due to the multidimensional nature of psychological distress at the end of life, encompassing an interplay between psychosocial and existential distress as well as physical symptom burden. Research shows that psychedelic-assisted therapy is an effective treatment of end of life...
Pharmacology & Therapeutics
August 1, 2023
Ryoichi Fujiwara, Megan Journey, Fatimah Al-Doori et al.
13 citations
Cannabis, cocaine, 3,4-methylenedioxymethamphetamine, and lysergic acid diethylamide are psychoactive substances with a significant increase in consumption during the 21st century due to their popularity in medicinal and recreational use. New psychoactive substances (NPSs) mimic established psychoactive substances. NPSs are known as being natural and safe to consumers; however, they are neither...
Frontiers in Psychiatry
July 11, 2023
Gniewko Więckiewicz, Iga Stokłosa, Maciej Stokłosa et al.
2 citations
Introduction Attention-deficit/hyperactivity disorder (ADHD) was originally treated as a neurodevelopmental disorder that occurs mainly in children and tends to diminish or disappear with age, but we now know that symptoms persist into adulthood in over 50% of ADHD patients. Undiagnosed individuals often turn to psychoactive substance to minimize the negative aspects of functioning and improve...
Schizophrenia Bulletin
July 1, 2023
Lorna Staines, Colm Healy, Felim Murphy et al.
Background and hypothesis: Psychotic experiences (PEs) are associated with increased risk for mental disorders, in particular persistent PEs. PEs therefore might be useful within intervention research. We sought to systematically determine the incidence and persistence of PEs in the general population. Study design: A double-blind search of databases (Embase, Pubmed PMC, Psychinfo, Medline, and...
Journal of integrative medicine
July 1, 2023
Biao Gao, Yi-Cui Qu, Meng-Yu Cai et al.
9 citations
This study investigated trends in the study of phytochemical treatment of post-traumatic stress disorder (PTSD). The Web of Science database (2007-2022) was searched using the search terms "phytochemicals" and "PTSD," and relevant literature was compiled. Network clustering co-occurrence analysis and qualitative narrative review were conducted. Three hundred and one articles were included in...
Brain Sciences
June 24, 2023
Mariana Campello De Oliveira, Mariana Capelo Vides, Dângela Layne Silva Lassi et al.
(1) Background: Synthetic cannabinoids (SCs) are emerging drugs of abuse sold as 'K2', 'K9' or 'Spice'. Evidence shows that using SCs products leads to greater health risks than cannabis. They have been associated with greater toxicity and higher addiction potential unrelated to the primary psychoactive component of marijuana, Δ9-tetrahydrocannabinol (Δ9-THC). Moreover, early cases of...
Frontiers in Psychiatry
June 15, 2023
Maria Bălăeţ, William Trender, Peter J. Hellyer et al.
11 citations
The large-scale disruption to peoples’ daily lives during the COVID-19 pandemic provides a context for examining whether use of substances such as psychedelics in a naturalistic (outside of a controlled environment) setting, is associated with better mental wellbeing and resilience relative to those who use other drugs, or who do not use drugs at all. We interrogate data from the Great British...